Neos Therapeutics Prices Public Offering At $5/Shr

(RTTNews) - Neos Therapeutics, Inc. (NEOS) announced that it has priced the public offering of 5 million shares of its common stock at $5.00 per share for $25 million. The company expects this offering to close on February 8, 2017.

In addition, Neos has granted the underwriters a 30-day option to purchase up to an additional 750,000 shares of common stock.

Neos has recently completed the resubmission of a New Drug Application to the FDA for Cotempla XR-ODT, its methylphenidate extended-release orally disintegrating tablet, for the treatment of ADHD. This is a Class 2 resubmission, with a target six-month PDUFA review period.

The company has also recently submitted another NDA for its amphetamine XR oral suspension drug candidate, NT-0201. The company expects sell these ADHD products by the end of 2017 alongside Adzenys XR-ODT, if approved.

NEOS closed Friday's regular trading session down 13% to $5.05.